AllCells Limited Liability Company (LLC) is a privately owned biotechnology company located in Berkeley, California, USA. AllCells is dedicated to providing human cells such as bone marrow cells, peripheral blood cells, cord blood cells, endothelial cells and total RNA/cDNA for scientific research in vitro. AllCells has been serving the needs of scientists in research laboratories for over 7 years and has earned an excellent reputation for its high quality products and services. AllCells is fully certified in accordance with Local, State and Federal business requirements. Its products are obtained from normal volunteers participating in an Institute Review Board (IRB) or Human Subject Committee approved donor program and each normal adult volunteer is screened for general health, HIV and hepatitis B and hepatitis C.
Xeragon was founded as a Swiss company specializing in the synthesis of oligoribonucleotides (RNA) in 1997. Xeragon is committed to meeting the needs of RNA scientists in the fields of biopharmaceuticals, diagnostics, therapeutics, and structural studies. We strive to produce high-quality products and deliver the very best in customer care. To keep up with the massively growing demand for synthetic RNA, we decided to move our RNA facility from Switzerland to the United States. Our expanded site in Huntsville, AL, USA has been fully operational since November 2001. Xeragon has a strong background in nucleoside chemistry, enabling us to develop many new methods and technologies. One of our groundbreaking developments is the TOM-Amidites (US Patent 5,986,084), which allow highly efficient chemical synthesis of RNA. Based on our TOM-Chemistry we can now produce RNA's of a higher quality than has ever been possible. We are proud to be able to share this breakthrough in RNA chemistry with our customers, and hope that this will contribute to understanding in this important area of scientific interest. On the 18th of April 2002 Xeragon was acquired by QIAGEN.
QIAGEN Genomics believes it was the world's first provider of commercial high throughput SNP genotyping services and is a leader in the innovation and development of such commercial products. The company to date has analyzed well over a million genotypes on behalf of its clients in the company's dedicated, first of its kind services facility. QIAGEN Genomics' proprietary Masscode system approach to SNP genotyping requires very small amounts of genomic DNA to perform extremely sensitive analyses. This can be a significant benefit considering the often very limited amounts of patient samples available. In addition, QIAGEN Genomics believes that analyses applying the Masscode tags are highly quantitative, accurate and cost effective. The company also offers nucleic acid extraction, DNA sequencing and other genomics-related services in addition to Masscode technology access programs. QIAGEN Genomics, formerly known as Rapigene, Inc., is located near Seattle, Washington.
Glen Research specializes in the supply of DNA synthesis reagents and RNA synthesis reagents. The company offers the widest range of phosphoramidites and solid supports for the chemical synthesis, modification, labelling, and purification of RNA and DNA oligonucleotides. We don't make oligos - Our customers do!
Elchrom Scientific AG - the name reflects our focus on electrophoresis and chromatography - was founded in 1988 by scientists of the Swiss Federal Institute of Technology (ETH) in Zurich. In 1994, the company merged with Guest Medical to form Guest Elchrom Scientific group, from which Elchrom Scientific AG was separated in 1997. The company headquarters, R & D laboratories and manufacturing facilities are in Switzerland. At Elchrom Scientific AG we have directed our efforts towards the development of new materials and methodologies for the separation of biological macromolecules. Several of the developments have been successfully completed, and we are strongly committed to further R & D activities in this challenging area.
Geneservice Limited aim to be the premier supplier of genomic products and technical services to both academic and commercial research organisations. It is our aim to deliver the highest quality product and customer service with the lowest turnaround time offering the greatest value for money. Geneservice make available genomic and proteomic libraries from a wide range of organisms in various formats (e.g. single clones, plates, pools, and high density filters) including the Mammalian Genome Collection (MGC) and IMAGE clones; and more recently RNAi libraries. Geneservice have invested in the latest genetic and genomic technologies so that you don't have to. Why invest in hardware, maintenance and training; only to discover that you've selected the wrong technology? We have the latest high-throughput hardware, managed by experts and this gives you the best in quality, turnaround times and pricing. Geneservice are a one-stop-shop for your gene discovery projects. Services include Whole Genome Amplification, DNA sequencing, microsatellite and SNP genotyping including 500K SNP mapping, and expression array analysis. There are currently about 30 staff at Geneservice. We have an experienced management team and a scientific team with wide-ranging genomic biology experience to help facilitate your project cost effectively.
RPI, at www.rpi.com , is a global leader in the development of ribozyme-based biotherapeutics and diagnostic tools for the treatment and monitoring of significant human diseases. Ribozymes are the product of Nobel Prize-winning research and are synthetically engineered to act as "molecular scissors" capable of cleaving target RNA in a highly specific manner, blocking gene expression and preventing production of unwanted proteins. In addition to its therapeutic and diagnostic pipeline, RPI is leveraging its broad-based nucleic acid technology for applications in genomics, proteomics, and individualized therapeutics. To date, RPI has spun out and licensed technology to atugen AG which is focused on target validation and additionally earlier this year announced a licensing agreement with Archemix, Inc. for the use of allosteric ribozymes in drug discovery and optimization and environmental monitoring. RPI holds equity positions in both companies and retains certain residual rights. RPI is currently engaged in negotiations with third parties concerning other possible strategic alliances. RPI's anti-hepatitis C virus ribozyme, HEPTAZYME(TM), is in Phase II clinical development in a multi-center trial in the U.S. RPI is partnered with Chiron Corporation for the development and commercialization of ANGIOZYME®, an anti-angiogenic ribozyme designed to inhibit the growth of new vasculature to supply blood to tumors and prevent tumor growth and metastasis, which is also in two Phase II clinical trials. Other RPI development projects include, HERZYME(TM), an anti-HER2 ribozyme for treatment of breast and other cancers in Phase I development and HepBzyme(TM), a ribozyme for the treatment of hepatitis B. The HERZYME program is being developed by an RPI/Elan business venture, Medizyme Pharmaceuticals Ltd. In addition, RPI is collaborating with Geron Corporation utilizing the expertise of each company to accelerate process development for Geron's lead telomerase inhibitor, GRN163. RPI also entered into an agreement with Fujirebio, Inc., the largest domestic diagnostic company in Japan, to develop and commercialize ribozyme-based clinical diagnostic products.
Apath, LLC is a drug discovery company focused on human viral diseases. Apath applies state-of-the art molecular virology and viral genetics to the discovery and development of novel therapeutic products for the treatment of viral infections. Apath's primary focus is on RNA viruses. Most medically important viruses are RNA viruses including hepatitis C virus, influenza virus, respiratory syncytial virus (RSV), and hemorrhagic fever viruses. Apath's founder and key employees have a proven track record and comprehensive expertise in virology and molecular biology. Apath has key patents, proprietary know-how, and license agreements related to hepatitis C virus (HCV) and other important human viral pathogens. In addition, Apath has a proprietary antiviral screening platform.
It is Q-RNA's mission to develop its novel drug target and discovery systems and use them to discover and optimize therapeutics to treat Alzheimer's disease (AD), a disorder with a large unmet medical need. With its initial focus on Alzheimer's disease, the Company will begin with a library of anti-amyloid compounds designed by a former founder of Neurochem, Inc. (NRMX) to dramatically improve on the compounds that Neurochem currently has in Phase II/III testing. In moving from a discovery to an integrated drug development company, Q-RNA believes that it can develop discovery tools and therapeutics for other amyloid or protein misfolding diseases including Parkinson's disease, type II diabetes, and possibly others. The Company's combination of best-in-class discovery/optimization tools, compound libraries, rational drug design and medicinal chemistry, will allow successful discovery of treatments that may slow down, interrupt, cure or even prevent Alzheimer's disease. It has the promise of identifying "blockbuster" category drugs with market potential in the multi-billions of dollars.
Calando Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing proprietary technologies that will lead to the therapeutic use of RNA interference, or "RNAi". We bring together multiple proven non-viral delivery technologies that overcome the primary hurdle to efficient RNAi delivery with world-class experience in the fields of medicine, RNAi therapeutics, drug delivery and materials design.
EPICENTRE®, founded in 1987, is a manufacturer and seller of high-quality molecular biology products for life science research, clinical research, molecular diagnostics and biopharmaceutical manufacturing. Products are available for transposon-based genetic analysis, DNA and RNA purification, DNA sequencing, PCR and RT-PCR amplification, DNA and RNA modifying enzymes, genomic cloning, in vitro transcription, and protein research.
Ellipsis Biotherapeutics Corporation is a privately held drug and diagnostic discovery company developing novel medicines for human diseases where existing therapies are unable to address patient needs. The company's lead programs are in Alzheimer's Disease and Inflammatory Bowel Disease, where new treatment regimens are needed not only to treat symptoms, but to prevent and cure the underlying disorder. Through both independent programs and strategic alliances, Ellipsis intends to commercialize its discoveries and make better medicines for patients.
Norgen Biotek offers plasmid amplification and purification services that can be customized to your needs. Norgen's team of skilled scientists uses their proprietary, resin-based system in order to obtain a plasmid preparation of the highest quality. We offer both competitive pricing and fast turnaround times. We are confident that Norgen's plasmid purification service will be able to meet your research needs. Norgen currently offers the following grade of DNA: Standard Research Grade This plasmid DNA can be used for standard research purposes such as cloning, sequencing, transformations, and transfections. These preparations are guaranteed to be free of genomic DNA, RNA and protein.
Mirus Bio Corporation is a biopharmaceutical company focused on discovering, developing and commercializing innovative nucleic acid based technologies and products. Under development are RNAi gene silencing therapies based on Mirus' proprietary Dynamic PolyConjugatesÔ delivery platform and gene therapies utilizing its Pathway IVÔ delivery protocol. Commercially, Mirus markets a range of innovative transfection and labeling research reagents worldwide. Dynamic PolyConjugates ("DPC") is a targeted systemic siRNA delivery platform. Our proprietary polymer based formulation chemistry efficiently targets gene silencing complexes to specific cells. As the DPCs attach to and enter the target cells, they respond to the environmental cues provided by the cell to disassemble and release the active siRNA molecule. This unique chemistry mimics the natural viral targeting and disassembly process. This technology is currently being optimized for liver and cancer tissues, and is actively being evaluated by select partners for research and clinical indications. Pathway IV is a clinically practical procedure based upon intravenous ("IV") delivery of plasmid DNA ("pDNA") to targeted limb muscle. With blood flow temporarily occluded by a tourniquet, a DNA solution is rapidly injected into a suitable vein. This elevates the pressure within the occlusion zone, making the blood vessel wall more permeable and allowing the pDNA to migrate into the adjoining muscle cells. Blood flow is then restored to normal within a few minutes, with only mild transient affects to the vasculature. This quick, robust procedure is being used as an enabling platform that will provide first-in-class therapeutic treatments for muscular dystrophy, peripheral ischemia and other diseases. Patients with the most common muscular dystrophies, Duchenne and Becker, suffer from a genetic defect in which dystrophin protein is either poor or inadequate in their muscle cells. It affects roughly 1 of every 3500 male births. MyoDys® will treat this disease by inserting a gene encoding active dystrophin into affected muscles to delay or prevent loss of muscle function. Peripheral ischemia is a condition in which reduced blood supply to limbs causes claudication (cramping), chronic pain, and potentially loss of the limb. It is common in diabetics and the elderly, where up to 20% of those over age 70 experience intermittent claudication. Mirus' treatment is based upon delivery of a gene encoding an angiogenic factor to the affected limb, which induces revascularization of the limb. In the future, the company envisions using muscle as the host site for gene therapies that induce secretion of therapeutic proteins to treat a range of diseases, including anemia, arthritis, ALS, and cancer immunotherapeutics. Mirus R&D uniquely integrates nucleic acid delivery and chemistry, a core competency which is unmatched in the industry. This serves as the foundation for both its novel research reagents and emerging therapeutics. The company maintains advanced research programs focused on synthetic siRNA delivery, and on gene delivery to liver and other target tissues. Access to Mirus' technologies is available through strategic alliances as well as licensing in nonstrategic fields. Mirus is well positioned to be a partner of choice due to its consistent record of profitability; driven by the sales growth of its research reagents.
RiboTargets is a privately owned pharmaceutical drug discovery company focused on the development of novel anti-bacterial and anti-cancer therapeutics. These therapeutic areas represent significant market opportunities. The Company has created and validated a proprietary structure-based drug discovery engine that allows the rapid identification and optimisation of drug candidates against both protein and nucleic acid targets using high throughput computer-aided and experimental drug design. Over the last four years, RiboTargets has made the transition from a technology platform company into a competitive drug discovery company. RiboTargets' goal for 2003 is to make the pivotal step from research into formal drug development. In the longer term, RiboTargets aims to become a significant player in the anti-bacterial and anti-cancer markets.
Benitec Limited is a ribonucleic acid interference (RNAi)-based therapeutics company using its deoxyribonucleic acid (DNA)-directed RNA interference (ddRNAi) technology to develop therapies for the treatment of life threatening diseases. The Company’s primary therapeutic program focuses on human immunodeficiency virus (HIV). Its other projects are in the area of infectious diseases and cancer. It also licenses its technology outside of its in-house programs in order to generate revenue to support its corporate and operational activities. During the fiscal year ended June 30, 2008 (fiscal 2008), the principal activity of the Company was the management, funding and commercialization of these projects. It operates in a single segment, including global commercialization (by licensing and partnering) of patents and licenses developed in the area of biotechnology, specifically in functional genomics, with applications in biomedical research and human therapeutics. (Source: ARS)
Promega Corporation is a global leader in providing innovative solutions for the life sciences industry. The company's 1,200 products enable scientists worldwide to advance knowledge in cellular analysis, proteomics, and genomics research with applications in drug discovery, molecular diagnostics, and human identification. Founded in 1978, the company is headquartered in Madison, Wisconsin, USA, and has extensive international distribution.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory